Skip to main content
Back
BIO logo

Bio-Rad Laboratories, Inc.

Data quality: 100%
BIO
NYSE Healthcare Medical - Devices
$273.60
▲ $1.48 (0.54%)
Mkt Cap: 7.38B
Day Range
$269.10 $276.14
52-Week Range
$211.43 $343.12
Volume
187,476
50D / 200D Avg
$287.77 / $286.16
Prev Close
$272.12

Quick Summary

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (631 peers)

Metric Stock Sector Median
P/E 9.7 0.2
P/B 1.0 3.0
ROE % 10.8 3.6
Net Margin % 29.4 3.8
Rev Growth 5Y % -3.0 10.0
D/E 0.2 0.2

Analyst Price Target

Hold
$327.50 +19.7%
Low: $320.00 High: $335.00
Forward P/E
26.69
Forward EPS
$10.25
EPS Growth (est.)
+0.0%
Est. Revenue
2.63B

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2029 $14.30
$14.03 – $14.57
 2.94B 1
FY2028 $12.53
$12.29 – $12.76
 2.80B 1
FY2027 $11.50
$11.28 – $11.71
 2.72B 2

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-12 $2.71 $2.51 -7.4%
2025-10-29 $2.30 $2.26 -1.7%
2025-07-31 $1.93 $2.61 +35.2%
2025-05-01 $1.73 $2.54 +46.8%
2025-02-13 $2.86 $2.90 +1.4%
2024-10-30 $1.28 $2.01 +57.0%
2024-08-01 $2.12 $3.11 +46.7%
2024-05-07 $2.15 $2.29 +6.5%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Key Takeaways

Revenue declined -3.04% annually over 5 years
ROE of 10.84% — decent returns on equity
Net margin of 29.42% shows strong profitability
Debt/Equity of 0.21 — conservative balance sheet
Generating 374.60M in free cash flow
P/E of 9.72 — trading at a low valuation

Growth

Revenue Growth (5Y)
-3.04%
Revenue (1Y)0.65%
Earnings (1Y)N/A
FCF Growth (3Y)31.01%

Quality

Return on Equity
10.84%
ROIC2.26%
Net Margin29.42%
Op. Margin10.47%

Safety

Debt / Equity
0.21
Current Ratio5.62
Interest Coverage5.52

Valuation

P/E Ratio
9.72
Forward P/E26.69
P/B Ratio0.99
EV/EBITDA30.99
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 0.65% Revenue Growth (3Y) -1.66%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -3.04% Earnings Growth (5Y) -34.99%
Profitability
Revenue (TTM) 2.58B Net Income (TTM) 759.90M
ROE 10.84% ROA 7.18%
Gross Margin 52.01% Operating Margin 10.47%
Net Margin 29.42% Free Cash Flow (TTM) 374.60M
ROIC 2.26% FCF Growth (3Y) 31.01%
Safety
Debt / Equity 0.21 Current Ratio 5.62
Interest Coverage 5.52
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 9.72 Forward P/E 26.69
P/B Ratio 0.99 P/S Ratio 2.86
PEG Ratio -0.08 Forward PEG N/A
EV/EBITDA 30.99 Fwd EV/EBITDA N/A
Forward P/S 2.81 Fwd Earnings Yield 3.75%
FCF Yield 5.07%
Market Cap 7.38B Enterprise Value 8.38B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2.58B 2.57B 2.67B 2.80B 2.92B
Net Income 759.90M -1.84B -637.32M -3.63B 4.25B
EPS (Diluted) 27.87 -65.36 -21.82 -121.79 140.83
Gross Profit 1.34B 1.38B 1.43B 1.57B 1.64B
Operating Income 270.50M 269.00M 337.80M 482.62M 500.34M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 10.58B 9.36B 12.30B 13.50B 17.80B
Total Liabilities 3.12B 2.79B 3.56B 3.89B 4.11B
Shareholders' Equity 7.45B 6.57B 8.74B 9.62B 13.69B
Total Debt 1.53B 1.37B 1.41B 1.39B 223.38M
Cash & Equivalents 531.80M 488.10M 403.80M 434.22M 470.78M
Current Assets 2.91B 3.03B 3.05B 3.16B 1.99B
Current Liabilities 517.00M 467.80M 522.80M 568.71M 680.94M

Strategy Scores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#625 of 826
31

Recent Activity

Exited Defensive Investing (Benjamin Graham)
Mar 26, 2026
Entered Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered Defensive Investing (Benjamin Graham)
Mar 24, 2026